Adenomatous Polyposis Coli Clinical Trial
Official title:
Post-Trial Access for Guselkumab in Patients With Familial Adenomatous Polyposis Who Are Experiencing Clinical Benefit After Completing 48 Weeks of Treatment in CNTO1959COR1001
The purpose of this post-trial access (PTA) program is to provide guselkumab to participants with Familial Adenomatous Polyposis (FAP) who are experiencing clinical benefit after completing 48 weeks of treatment in Study CNTO1959COR1001.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00585312 -
Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)
|
Phase 3 | |
Completed |
NCT03095703 -
Sirolimus and Familial Adenomatous Polyposis (FAP)
|
Phase 2 | |
Completed |
NCT03649971 -
A Study of Guselkumab in Participants With Familial Adenomatous Polyposis
|
Phase 1 | |
Completed |
NCT05014360 -
A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis
|
Phase 1 | |
Completed |
NCT01604564 -
Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis Patients
|
||
Recruiting |
NCT05919264 -
FOG-001 in Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02113202 -
Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW
|
Phase 1 | |
Withdrawn |
NCT03027401 -
Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics
|
||
Recruiting |
NCT06435533 -
Cold Atmospheric Plasma for the Endoscopic Treatment of Duodenal Polyps in Patients With Familial Adenomatous Polyposis
|
N/A | |
Terminated |
NCT00140894 -
A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)
|
Phase 4 | |
Active, not recruiting |
NCT01187901 -
A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients
|
Phase 2 | |
Recruiting |
NCT00319007 -
Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis
|
Phase 2 |